Auvi-q
(Epinephrine)Dosage & Administration
The recommended dosage of AUVI-Q is based on weight. (
The recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1. Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
| Patient’s Weight | Dosage |
| 30 kg or greater | AUVI-Q 0.3 mg |
| 15 kg to less than 30 kg | AUVI-Q 0.15 mg |
| 7.5 kg to less than 15 kg | AUVI-Q 0.1 mg |
| Patient’s Weight | Dosage |
| 30 kg or greater | AUVI-Q 0.3 mg |
| 15 kg to less than 30 kg | AUVI-Q 0.15 mg |
| 7.5 kg to less than 15 kg | AUVI-Q 0.1 mg |
In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose. (
The recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1. Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
| Patient’s Weight | Dosage |
| 30 kg or greater | AUVI-Q 0.3 mg |
| 15 kg to less than 30 kg | AUVI-Q 0.15 mg |
| 7.5 kg to less than 15 kg | AUVI-Q 0.1 mg |
By using PrescriberAI, you agree to the AI Terms of Use.
Auvi-Q Prescribing Information
AUVI-Q is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 7.5 kg or greater.
The recommended dosage of AUVI-Q is based on weight. (
The recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1. Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
| Patient’s Weight | Dosage |
| 30 kg or greater | AUVI-Q 0.3 mg |
| 15 kg to less than 30 kg | AUVI-Q 0.15 mg |
| 7.5 kg to less than 15 kg | AUVI-Q 0.1 mg |
- Since the doses of epinephrine delivered from AUVI-Q are fixed, use other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.
- In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose.
- Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.
- It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times.
- Each AUVI-Q contains a single dose of epinephrine for single use.
- Visually inspect the epinephrine solution in the viewing window of AUVI-Q for particulate matter, cloudiness, and discoloration prior to administration.
- Instruct caregivers of young children and infants who are prescribed AUVI-Q and who may be uncooperative and kick or move during an injection to hold the child’s leg firmly in place and limit movement prior to and during an injection[see Warnings and Precautions ].
- Inject AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Do not inject intravenously, and do not inject into buttocks, digits, hands or feet[see Warnings and Precautions ].
- If a second dose is needed, administer a new AUVI-Q starting 5 minutes after the first dose. More than two sequential doses of epinephrine should be administered under direct medical supervision. Refer patients and caregivers to the Instructions for Use for detailed administration instructions.
| Patient’s Weight | Dosage |
| 30 kg or greater | AUVI-Q 0.3 mg |
| 15 kg to less than 30 kg | AUVI-Q 0.15 mg |
| 7.5 kg to less than 15 kg | AUVI-Q 0.1 mg |
In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose. (
The recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1. Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
| Patient’s Weight | Dosage |
| 30 kg or greater | AUVI-Q 0.3 mg |
| 15 kg to less than 30 kg | AUVI-Q 0.15 mg |
| 7.5 kg to less than 15 kg | AUVI-Q 0.1 mg |
- Since the doses of epinephrine delivered from AUVI-Q are fixed, use other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.
- In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose.
- Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.
- It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times.
- Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. ()
2.1 Recommended DosageThe recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1. Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
Table 1. Recommended Dosage of AUVI-Q Based on Patient’s WeightPatient’s Weight Dosage 30 kg or greater AUVI-Q 0.3 mg 15 kg to less than 30 kg AUVI-Q 0.15 mg 7.5 kg to less than 15 kg AUVI-Q 0.1 mg - Since the doses of epinephrine delivered from AUVI-Q are fixed, use other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.
- In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose.
- Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.
- It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times.
- It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times. ()
2.1 Recommended DosageThe recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1. Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
Table 1. Recommended Dosage of AUVI-Q Based on Patient’s WeightPatient’s Weight Dosage 30 kg or greater AUVI-Q 0.3 mg 15 kg to less than 30 kg AUVI-Q 0.15 mg 7.5 kg to less than 15 kg AUVI-Q 0.1 mg - Since the doses of epinephrine delivered from AUVI-Q are fixed, use other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.
- In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose.
- Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.
- It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times.
- See full prescribing information for administration instructions. ()
2.2 Administration Instructions- Each AUVI-Q contains a single dose of epinephrine for single use.
- Visually inspect the epinephrine solution in the viewing window of AUVI-Q for particulate matter, cloudiness, and discoloration prior to administration.
- Instruct caregivers of young children and infants who are prescribed AUVI-Q and who may be uncooperative and kick or move during an injection to hold the child’s leg firmly in place and limit movement prior to and during an injection[see Warnings and Precautions ].
- Inject AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Do not inject intravenously, and do not inject into buttocks, digits, hands or feet[see Warnings and Precautions ].
- If a second dose is needed, administer a new AUVI-Q starting 5 minutes after the first dose. More than two sequential doses of epinephrine should be administered under direct medical supervision. Refer patients and caregivers to the Instructions for Use for detailed administration instructions.
Injection:
- 0.3 mg (0.3 mg/0.3 mL) epinephrine injection, USP, clear and colorless solution, single-dose prefilled autoinjector
- 0.15 mg (0.15 mg/0.15 mL) epinephrine injection, USP, clear and colorless solution, single-dose prefilled autoinjector
- 0.1 mg (0.1 mg/0.1 mL) epinephrine injection, USP, clear and colorless solution, single-dose prefilled autoinjector
Elderly patients may be at greater risk of developing adverse reactions. (
Clinical studies of AUVI-Q for emergency treatment of type I allergic reactions, including anaphylaxis, were not conducted to determine whether they respond differently from younger patients. However, other reported clinical experience with use of epinephrine for treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, these patients may be at greater risk for developing adverse reactions after epinephrine administration
None.
- Do not inject intravenously, into buttock, digits, hands, or feet. ()
5.1 Injection-Related ComplicationsAUVI-Q should only be injected into the anterolateral aspect of the thigh
[see Dosage and Administration ].- Do not inject intravenously.Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine for this inadvertent administration.
- Do not inject into buttock.Injection into the buttock may not provide effective treatment of anaphylaxis. If AUVI-Q is injected into the buttock, advise the patient to administer a second dose of AUVI-Q into the anterolateral aspect of the thigh and if symptoms worsen or persist, then go immediately to the nearest emergency room for further treatment of anaphylaxis. Additionally, injection into the buttock has been associated with Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk.
- Do not inject into digits, hands or feet.Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area and may not provide effective treatment of anaphylaxis. Advise the patient to administer a second dose of AUVI-Q into the anterolateral aspect of the thigh if experiencing anaphylaxis and then go immediately to the nearest emergency room and inform the healthcare provider in the emergency room of the location of the accidental injection. Treatment of such inadvertent administration should consist of vasodilation, in addition to further appropriate treatment of anaphylaxis[see Adverse Reactions ].
- Hold leg firmly during injection.To minimize the risk of injection-related injury when administering AUVI-Q to young children or infants, instruct caregivers to hold the child’s leg firmly in place and limit movement prior to and during injection.
- Hold the child’s leg firmly in place and limit movement prior to and during injection when administering to young children or infants to minimize the risk of injection-related injury. ()
5.1 Injection-Related ComplicationsAUVI-Q should only be injected into the anterolateral aspect of the thigh
[see Dosage and Administration ].- Do not inject intravenously.Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine for this inadvertent administration.
- Do not inject into buttock.Injection into the buttock may not provide effective treatment of anaphylaxis. If AUVI-Q is injected into the buttock, advise the patient to administer a second dose of AUVI-Q into the anterolateral aspect of the thigh and if symptoms worsen or persist, then go immediately to the nearest emergency room for further treatment of anaphylaxis. Additionally, injection into the buttock has been associated with Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk.
- Do not inject into digits, hands or feet.Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area and may not provide effective treatment of anaphylaxis. Advise the patient to administer a second dose of AUVI-Q into the anterolateral aspect of the thigh if experiencing anaphylaxis and then go immediately to the nearest emergency room and inform the healthcare provider in the emergency room of the location of the accidental injection. Treatment of such inadvertent administration should consist of vasodilation, in addition to further appropriate treatment of anaphylaxis[see Adverse Reactions ].
- Hold leg firmly during injection.To minimize the risk of injection-related injury when administering AUVI-Q to young children or infants, instruct caregivers to hold the child’s leg firmly in place and limit movement prior to and during injection.
- Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection. ()
5.2 Serious Infections at the Injection SiteRare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis.
Clostridiumspores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce the presence of bacteria on the skin, alcohol cleansing does not killClostridiumspores. To decrease the risk ofClostridiuminfection, do not inject AUVI-Q into the buttock[see Warnings and Precautions ]. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site. - Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias. ()
5.3 Risk Associated with Use of Epinephrine in Certain Coexisting ConditionsSome patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, instruct patients with these conditions, and/or caregivers to the circumstances under which epinephrine should be used.
Administer epinephrine with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias
[see Drug Interactions and Adverse Reactions ].Epinephrine can temporarily exacerbate the underlying conditions or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Administer epinephrine with caution in patients with these conditions, including elderly patients and pregnant women.
- May aggravate certain coexisting conditions. ()
5.3 Risk Associated with Use of Epinephrine in Certain Coexisting ConditionsSome patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, instruct patients with these conditions, and/or caregivers to the circumstances under which epinephrine should be used.
Administer epinephrine with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias
[see Drug Interactions and Adverse Reactions ].Epinephrine can temporarily exacerbate the underlying conditions or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Administer epinephrine with caution in patients with these conditions, including elderly patients and pregnant women.
- The presence of a sulfite in this product should not deter use. ()
5.4 Allergic Reactions Associated with SulfiteEpinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though AUVI-Q contains sodium bisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite in AUVI-Q should not deter administration of the drug for treatment of serious allergic or other emergency situations.